Author: admin

CHINO, Colombia (Aug. 9, 2024) ¬– U.S. Army veterinary technician Pfc. Ismael Hamilton, assigned to the 248th Medical Detachment Veterinary Service Support, reaches toward a dog at a mobile animal care site in Chino, Colombia during Continuing Promise 2024. Continuing Promise 2024, a U.S. Naval Forces Southern Command-led mission, features multinational coordination, collaboration, and caring through partner-led events, where U.S. military personnel, civilian mariners, civilian professionals, and volunteers conduct “diplomacy through good deeds,” which improve local infrastructure, bolster collective capabilities and skills, and facilitate an environment of collaborative learning. (U.S. Navy photo by Mass Communication Specialist Seaman Jasmin L. Aquino)…

In today’s competitive biologics and gene therapy landscape, CDMO quality control teams are under pressure to deliver faster tech transfer, reduce costs, and maintain consistently high product quality. As molecules become more complex, with AAV partial capsids, aggregates, and heterogeneous populations increasingly common, traditional analytical technologies often create bottlenecks that impact timelines and productivity.Mass photometry (MP) is a rapid, label‑free, single‑particle mass measurement technique that provides native‑state insight into product quality in minutes using minimal sample. It can complement established orthogonal methods like AUC, delivering actionable data earlier, more frequently, and with lower operational burden.In this GEN webinar Ray Zhang,…

Startups building science-grounded, consumer-ready healthspan solutions invited to pitch live in London in June 2026. The longevity sector is moving fast – capital is pouring in, clinics are popping up on every corner, and ‘prevention’ is finally moving from a biohacker’s hobby to a serious policy conversation. But for the founders stuck in the gap between a brilliant lab insight and an actual customer’s daily life, getting noticed is still an uphill battle. It’s relatively easy to show off impressive data in a petri dish or a computer model; it’s a much taller order to prove a product can survive…

Credit: koto_feja / Getty Images New findings from researchers at City St George’s, University of London indicate that providing patients with a second cancer treatment while a tumor is still shrinking under a first-line therapy could outperform current methods of retreating the cancer after relapse. The study, published in the journal Genetics, adapted mathematical models of evolutionary rescue theory of how plants and animals evolve in response to environmental pressures to discover how a second treatment before tumors have gained resistance mutations can improve cancer treatments. Commenting on what the St. George’s team called a “kick it while it’s down”…

A researcher working at Kite, a Gilead Company. Kite’s parent company Gilead Sciences has agreed to acquire Arcellx for $7.8 billion, in a deal intended to give the buyer full control of the buyout target’s lead candidate, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma that Kite and Arcellx have partnered on developing for more than three years. [Kite, a Gilead Company] Gilead Sciences has agreed to acquire Arcellx for $7.8 billion, the companies said today, in a deal intended to give the buyer full control of the buyout target’s lead candidate, a BCMA-directed…

Coenzyme Q10, often called CoQ10, is one of those quiet, indispensable molecules that rarely makes headlines, yet quietly sustains nearly every cell in our bodies. It sits deep within our mitochondria, helping transform the food we eat into usable energy. It also serves as a powerful antioxidant, protecting delicate cellular structures from oxidative stress. But here’s something we don’t often consider: what if our ability to maintain healthy CoQ10 levels depends not only on our own cells, but on the balance of microbes living within us? Let’s explore that connection. CoQ10: An Energy Molecule with Microbial Roots CoQ10 (ubiquinone) is…

AGBT hasn’t even started, and Ultima Genomics is out of the gate, with a Monday morning announcement of the launch of the second generation of its platform: the UG 200 series and next-generation Solaris 2.0 workflow. “We have doubled down on our strengths and closed our gaps,” noted Gilad Almogy, PhD, Ultima’s CEO. “We made our existing technology into a better platform, all around, with half the footprint, twice the output, and half the runtime.” “It’s like a beast now,” he asserted. The company is launching two new instruments: the UG 200 single wafer and the UG 200 Ultra dual…

A once-a-month GLP-1/GIP drug candidate moves into US trials, signaling a new phase for metabolic medicine and longevity investing. Could a once-a-month injection finally make weight loss easier and healthier over the long run? That is the question. Scientists and clinicians have wrestled with a stubborn question: how do you make lasting weight loss simple, safe, and sustainable? CSPC Pharmaceutical Group thinks it has a solution. Their investigational therapy, SYH2082, has just received approval from the US Food and Drug Administration (FDA) to begin clinical trials in the United States, a major milestone for the Hong Kong-based company [1]. This…

Credit: 7activestudio / Getty Images Research led by Harvard Medical School shows the level of plaque clogging a person’s arteries is likely more relevant for judging heart attack risk in men than in women. The study, published in Circulation: Cardiovascular Imaging, showed that while women have significantly lower levels of coronary artery plaque than men, this does not necessarily translate to lower risk for cardiovascular disease and events such as heart attacks. Heart disease is the main cause of death for both men and women in the U.S., but it is becoming increasingly clear that symptoms and risks for this…

Paragon’s latest venture targets Alzheimer’s via delivery platform designed to cross the blood-brain barrier. US biotech Korsana Biosciences has emerged from stealth with $175 million in funding and a focus on developing next-generation biologics designed to reach the brain more effectively and improve the treatment of neurodegenerative diseases. The Waltham, Massachusetts-based company is the sixth biotech to emerge from the stable of venture creator Paragon Therapeutics, and is initially targeting Alzheimer’s disease with its lead antibody program, supported by a proprietary platform designed to overcome long-standing drug delivery challenges associated with the blood-brain barrier. Korsana’s strategy is built on a…